Login to your account

Username *
Password *
Remember Me

Blog With Right Sidebar

Adaptation, Evaluation, and Updating of Guidelines: Article 14 in Integrating and Coordinating Efforts in COPD Guideline Development. An Official ATS/ERS Workshop Report.

Adaptation, Evaluation, and Updating of Guidelines: Article 14 in Integrating and Coordinating Efforts in COPD Guideline Development. An Official ATS/ERS Workshop Report.

Proc Am Thorac Soc. 2012 Dec;9(5):304-310

Authors: Burgers JS, Anzueto A, Black PN, Cruz AA, Fervers B, Graham ID, Metersky M, Woodhead M, Yawn BP, on behalf of the ATS/ERS Ad Hoc Committee on Integrating and Coordinating Efforts in COPD Guideline Development

Abstract
Introduction: Professional societies, like many other organizations, have recognized the need to use more rigorous processes to ensure that health care recommendations are informed by the best available research evidence. This is the last of a series of 14 articles that methodologists and researchers from around the world have prepared to advise guideline developers in respiratory and other diseases on how to achieve this. We updated a review of the literature on guideline adaptation, evaluation, and updating, focusing on four key questions. Methods: In this review we addressed the following questions. (1) Which high-quality guidelines on chronic obstructive pulmonary disease (COPD) are available? (2) How should guidelines be adapted to the user's context and culture? (3) How should the use of guidelines be evaluated in clinical practice? and (4) How should guidelines be efficiently kept up-to-date? We did not conduct systematic reviews ourselves. We relied on a literature review published in 2006 and on a manual produced by the ADAPTE Collaboration to inform our judgments, as well as our collective experience and workshop discussions. Results and Discussion: Guideline adaptation can be seen as an alternative to de novo development and as part of an implementation process, taking into consideration the user's own context. A systematic approach should be followed to ensure high quality of the resulting guidance. On the topic of COPD, many guidelines are available. Guidelines of the Global Initiative for Chronic Obstructive Lung Disease and of the American Thoracic Society and European Respiratory Society are particularly well-suited for adaptation. The adaptation process includes (1) definition of specific questions that need to be answered by the guideline; (2) assessment of guideline quality; (3) assessment of the clinical content, validity, acceptability, applicability, and transferability of the recommendations; and (4) decisions about adoption or adaptation of the recommendations. The use of the guidelines in practice can be measured with performance indicators. Adverse effects of strict adherence to guideline recommendations should be prevented, in particular when the improvement of patient outcomes is unclear. COPD guidelines should be updated at least every 2 years. Collaboration between COPD guideline developers is recommended to prevent duplication of effort.

PMID: 23256175 [PubMed - as supplied by publisher]

Hypereosinophilic obliterative bronchiolitis: a distinct, unrecognised syndrome.

Hypereosinophilic obliterative bronchiolitis: a distinct, unrecognised syndrome.

Eur Respir J. 2012 Dec 20;

Authors: Cordier JF, Cottin V, Khouatra C, Revel D, Proust C, Freymond N, Thivolet-Béjui F, Glérant JC

Abstract
Background: Only isolated biopsy-proven cases of eosinophilic bronchiolitis have been reported, all from Japan.Methods: We present 6 patients with hypereosinophilic obliterative bronchiolitis (HOB), defined by the following criteria: 1-blood eosinophil cell count>1 G·L(-1) and/or BAL eosinophil count>25%, 2-persistent airflow obstruction despite high-dose inhaled bronchodilators and corticosteroids, 3-eosinophilic bronchiolitis at lung biopsy (n=2) and/or direct signs of bronchiolitis (centrilobular nodules, branching opacities) on computed tomography (n=6).Results: Chronic dyspnoea and cough often severe, without the characteristic features of asthma, were the main clinical manifestations. Atopy and asthma were present in the history of 3 and 2 patients, respectively. One patient met biological criteria of the lymphoid variant of idiopathic hypereosinophilic syndrome. Mean blood eosinophil cell count was 2.7 G·L(-1) and mean eosinophil differential percentage at bronchoalveolar lavage was 63%. Mean initial FEV1/FVC ratio was 50%, normalising with oral corticosteroid therapy in all patients. HOB manifestations recurred when oral prednisone was decreased to 10-20 mg·day(-1), but higher doses controlled the disease.Conclusion: HOB is a characteristic entity deserving to be individualised among the eosinophilic respiratory disorders. Thorough analysis is needed to determine whether unrecognised and/or smouldering HOB may further be a cause of irreversible airflow obstruction in chronic eosinophilic respiratory diseases.

PMID: 23258778 [PubMed - as supplied by publisher]

Respiratory muscle function in interstitial lung disease.

Respiratory muscle function in interstitial lung disease.

Eur Respir J. 2012 Dec 20;

Authors: Walterspacher S, Schlager D, Walker DJ, Müller-Quernheim J, Windisch W, Kabitz HJ

Abstract
Interstitial lung diseases (ILD) limit daily activities, impair quality of life and result in (exertional) dyspnoea. This has mainly been attributed to a decline in lung function and impaired gas exchange. However, the contribution of respiratory muscle dysfunction to these limitations remains to be conclusively investigated.ILD patients and matched controls performed body plethysmography, a standardized 6-minute walking test, volitional (respiratory drive: P0.1, global maximal inspiratory mouth occlusion pressure: PImax, sniff nasal pressure: SnPna, inspiratory muscle load) and non-volitional tests on respiratory muscle function and strength (twitch mouth and transdiaphragmatic pressure during bilateral magnetic phrenic nerve stimulation: TwPmo,TwPdi).25 patients and 24 controls were included in the study. PImax and SnPna remained unaltered (both p>0.05), whereas P0.1 and the load on the inspiratory muscles were higher (both p<0.05) in ILD patients compared to controls. TwPmo and TwPdi were lower in ILD patients (TwPmo: 0.86SD0.4vs1.32SD0.4,p<0.001; TwPdi 1.34SD0.6vs1.88SD0.5,p=0.022).Diaphragmatic force generation seems to be impaired in this cohort of ILD patients while global respiratory muscle strength remains preserved. Central respiratory drive and the load imposed on the inspiratory muscles are increased. Whether impaired respiratory muscle function impacts morbidity and mortality in ILD patients needs to be investigated in future studies.

PMID: 23258788 [PubMed - as supplied by publisher]

Systemic biomarkers in the evaluation and management of COPD patients: are we getting closer to clinical application?

Systemic biomarkers in the evaluation and management of COPD patients: are we getting closer to clinical application?

Curr Drug Targets. 2012 Dec 17;

Authors: Kostikas K, Bakakos P, Papiris S, Stolz D, Celli BR

Abstract
Chronic obstructive pulmonary disease (COPD) is a complex, multicomponent disease at the clinical, cellular, and molecular levels. Over the past few years there has been a growing interest in the field of biomarkers in COPD and a large number of studies have evaluated potential candidate molecules in different patient settings. Data on systemic biomarkers from large cohorts, including the well-characterized population of the ECLIPSE study, are now available and provide exciting information on the association of biomarkers with clinically important outcomes, including exacerbations, hospitalizations and mortality. Moreover, recent research has provided proof for the existence of distinct "systemic inflammatory" phenotypes. This review summarizes the currently available evidence on systemic biomarkers in COPD, providing clinically relevant information on the possible role of systemic biomarkers in the evaluation of disease activity and severity, phenotypes, outcomes, COPD exacerbations and treatment response and guidance. Despite the fact that no single biomarker is currently ready to characterize sufficiently the status of COPD patients, guide treatment options, and predict future events, our current knowledge is definitely more advanced than a few years ago and the future of biomarkers looks even more promising.

PMID: 23256717 [PubMed - as supplied by publisher]

Inhaled Corticosteroids in COPD: Pros and Cons.

Inhaled Corticosteroids in COPD: Pros and Cons.

Curr Drug Targets. 2012 Dec 17;

Authors: Zervas E, Samitas K, Gaga M, Beghe B, Fabbri LM

Abstract
Chronic obstructive pulmonary disease (COPD) is a devastating illness characterized by airway and systemic inflammation, progressive airway obstruction and exacerbations. It is a major cause of chronic morbidity and mortality, projected to be the third leading cause of death by the year 2020. Although there is currently no definite cure, COPD is both a preventable and treatable disease. Important changes in our perspective and understanding of the disease have been made that lead to marked improvements in the treatment of COPD, such as the use of long-acting anticholinergics, β2 agonists and inhaled corticosteroids (ICS). Current GOLD guidelines call for the use of ICS in patients with severe and very severe airflow limitation and/or for patients with frequent exacerbations. This population constitutes only around 20% of all COPD patients, however current data show that as much as 70% are prescribed ICS. Although widely used, clinical trials on the efficacy of ICS in COPD have been up to now inconclusive or even contradictory. This has lead to wide confusion and debate regarding their role in the management of COPD. This review summarizes all current knowledge originating from observational studies, randomized clinical trials and expert views regarding ICS therapy in COPD. Arguments in favor and against the use of ICS are presented with respect to airway and systemic inflammation, exacerbation frequency and severity, lung function decline, quality of life, mortality and adverse events.

PMID: 23256718 [PubMed - as supplied by publisher]

Search